Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Cited by Google
Similars in SciELO
Similars in Google
Share
Revista de la Facultad de Medicina
Print version ISSN 0120-0011
Abstract
ESCOBAR, Hellmann Adrián et al. Pharmacological treatment of patent ductus arteriosus in premature infants. rev.fac.med. [online]. 2019, vol.67, n.2, pp.333-339. ISSN 0120-0011. https://doi.org/10.15446/revfacmed.v67n2.64146.
Introduction:
Pharmacological management ofpatent ductus arteriosus (PDA) usually includes non-selective inhibitors of the enzyme cyclooxygenase, especially indomethacin and ibuprofen. Recently, acetaminophen has also been suggested as a therapeutic alternative.
Objective:
To conduct a narrative review of the literature on pharmacological management of PDA.
Materials and methods:
Structured literature search conducted on the ProQuest, EBSCO, ScienceDirect, PubMed, LILACS, Embase, Trip Database, SciELO and Cochrane Library databases, with the terms "Ductus Arteriosus, patentAND therapeutics"; "Ductus Arteriosus, patent AND indometacin"; "Ductus Arteriosus, Patent AND ibuprofen", and "Ductus Arteriosus, patent AND acetaminophen", and their equivalents in Spanish.
Results:
69 articles had relevant information to carry out the present review.
Conclusions:
In premature infants, the mainstay of pharmacological treatment for PDA continues to be non-selective cyclooxygenase inhibitors, indomethacin and ibuprofen, all with similar safety and efficacy profiles. The available evidence suggests that acetaminophen may be a useful alternative for management, but it is insufficient to make definitive recommendations regarding the efficacy and safety of this drug.
Keywords : Ductus Arteriosus, Patent; Therapeutics; Indomethacin; Ibuprofen; Acetaminophen; Anti-Inflammatory Agents; Non-Steroidal (MeSH).